Arsenic trioxide—an old drug rediscovered

A Emadi, SD Gore - Blood reviews, 2010 - Elsevier
Over the last 17years, clinical trials conducted worldwide have demonstrated the efficacy of
arsenic trioxide (As2O3) in the treatment of relapsed acute promyelocytic leukemia (APL) …

Arsenical-based cancer drugs

PJ Dilda, PJ Hogg - Cancer treatment reviews, 2007 - Elsevier
Arsenic is a semi-metal or metalloid with two biologically important oxidation states, As (III)
and As (V). As (III), in particular, reacts with closely spaced protein thiols, forming stable …

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience

S Park, S Grabar, C Kelaidi… - Blood, The Journal …, 2008 - ashpublications.org
We analyzed prognostic factors of response, response duration, and possible impact on
survival of epoetin α, epoetin β, or darbepoetin α (DAR) with or without granulocyte colony …

The myelodysplastic syndromes: diagnosis and treatment

DP Steensma, JM Bennett - Mayo Clinic Proceedings, 2006 - Elsevier
The myelodysplastic syndromes (MDSs) are common, acquired, clinically challenging
hematologic conditions that are characterized by bone marrow failure and a risk of …

Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies

D Douer, MS Tallman - Journal of clinical oncology, 2005 - ascopubs.org
Arsenic trioxide has shown great promise in the treatment of patients with relapsed or
refractory acute promyelocytic leukemia (APL). In clinical trials, arsenic trioxide induces …

Anticancer activity of small-molecule and nanoparticulate arsenic (III) complexes

EP Swindell, PL Hankins, H Chen… - Inorganic …, 2013 - ACS Publications
Starting in ancient China and Greece, arsenic-containing compounds have been used in the
treatment of disease for over 3000 years. They were used for a variety of diseases in the …

Developmentally Restricted Genetic Determinants of Human Arsenic Metabolism: Association between Urinary Methylated Arsenic and CYT19 Polymorphisms in …

MM Meza, L Yu, YY Rodriguez, M Guild… - Environmental …, 2005 - ehp.niehs.nih.gov
We report the results of a screen for genetic association with urinary arsenic metabolite
levels in three arsenic metabolism candidate genes, PNP, GSTO, and CYT19, in 135 arsenic …

Myelodysplasic syndromes: a comprehensive review

DVT Catenacci, GJ Schiller - Blood reviews, 2005 - Elsevier
Myelodysplastic syndromes (MDS) are a set of oligoclonal disorders of hematopoietic stem
cells characterized by ineffective hematopoiesis that manifest clinically as anemia …

EVI1 and hematopoietic disorders: history and perspectives

G Nucifora, L Laricchia-Robbio, V Senyuk - Gene, 2006 - Elsevier
The ecotropic viral integration site 1 (EVI1) gene was identified almost 20 years ago as the
integration site of an ecotropic retrovirus leading to murine myeloid leukemia. Since its …

Myelodysplastic syndromes: molecular pathogenesis and genomic changes

F Nolte, WK Hofmann - Annals of hematology, 2008 - Springer
Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis
presenting with peripheral cytopenias in combination with a hyperplastic bone marrow and …